Kelun Pharmaceutical (002422) Semi-annual Report Comment: New Products Smoothly Quantitatively R & D Takes Firm International Step Event: The company …
March 2020
Quartz (603688) company dynamic comment： convertible bonds approved for 6000 tons of electronic-grade quartz expansion
Quartz (603688) company dynamic comment: convertible bonds approved for 6000 tons of electronic-grade quartz expansion Event: Company public offering 3.The …
Chengdi shares (603887)： Consolidated results are underestimated by IDC
Chengdi shares (603887): Consolidated results are underestimated by IDC Event: The company announced the third quarter report of 2019 and …
Haige Communication (002465)： Second-quarter performance growth rate to increase long-term performance, high growth can be expected
Haige Communication (002465): Second-quarter performance growth rate to increase long-term performance, high growth can be expected Incident Description On August …
Kechuangban Pharmaceutical and Biological Company Research Series： Nanwei Medical (688029)
Kechuangban Pharmaceutical and Biological Company Research Series: Nanwei Medical (688029) Core views: 1. The company’s main business: The company is …
Ping An of China (601318)： Key indicators are still improving
Ping An of China (601318): Key indicators are still improving Summary and suggestions: Ping An released its annual report, and …
Beijing-Shanghai High Speed Rail (601816) First Coverage Report： Gold Line in National Railways Optimistic about Long-Term Value of the Company
Beijing-Shanghai 杭州夜网 High Speed Rail (601816) First Coverage Report: Gold Line in National Railways Optimistic about Long-Term Value of the …
Hanlan Environment (600323)： The peak of the commissioning of the convertible bonds will bring rapid growth in performance
Hanlan Environment (600323): The peak of the commissioning of the convertible bonds will bring rapid growth 无锡夜网 in performance Company …
Ruikang Pharmaceutical (002589) 2019 Interim Report Comments： Cash Flow Continues to Improve, Devices Continue to Maintain High Growth Rate
Ruikang Pharmaceutical (002589) 2019 Interim Report Comments: Cash Flow Continues to Improve, Devices Continue to Maintain High Growth Rate The …
Shanxi Coking (600740)： Significant return on investment in coking coal is expected to benefit from rising coking coal volume and price
Shanxi Coking (600740): Significant return on investment in coking coal is expected to benefit from rising coking coal volume and …